Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Article Type
- Clinical Trial1
- Clinical Study1
- Comparative Study1
- Controlled Clinical Trial1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Ann Allergy1
Search Results
Sort by
- Book[edited by] Tommaso Falcone, MD, FRCS(C), FACOG, Professor of Surgery, ... Show More Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Chairman of Department of Obstetrics and Gynecology & Women's Health Institute, Cleveland Clinic, Cleveland, Ohio, M. Jean Uy-Kroh, MD, FACOG, Assistant Professor of Surgery, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Department of Obstetrics and Gynecology & Women's Health Institute, Director, Chronic Pelvic Pain Program, Cleveland Clinic, Cleveland, Ohio, Linda D. Bradley, MD, FACOG, Professor of Surgery, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Vice Chairman of Department of Obstetrics and Gynecology & Women's Health Institute, Director, Center for Fibroid and Menstrual Disorders, Cleveland Clinic, Cleveland, Ohio.
- ArticleMahajan VK, Tomashefski JF, Huber GL.Ann Allergy. 1977 Nov;39(5):319-24.Albuterol, a new bronchodilator drug known to cause beta2-adrenergic receptor stimulation, was compared with isoproterenol sulphate for their pulmonary and cardiovascular effects in patients suffering from bronchial asthma. In a double-blind manner 24 patients received as aerosol 170 micrograms of Albuterol or 150 micrograms of Isoproterenol or placebo on three different days. Spirometric, plethysmographic, heart rate and blood pressure measurements were made at 1, 5, 15, 30, 60, 90, 120, 300 and 360 minutes after drug inhalation. Baseline values for the various indices were not significantly different before administration of the drugs. Results demonstrate that Albuterol is an effective bronchodilator and its bronchodilating effect is significantly superior and of longer duration than that of Isoproterenol. Albuterol did not produce any significant changes in blood pressure and pulse rate, thus confirming its selectivity for beta2 receptors.